Quiet the pain.
Lengthen the healthspan.

CBD Gummies — 25 mg

Broad-spectrum CBD in a pectin-based gummy. Supports inflammation management, relaxation, and sleep onset by modulating CB1/CB2 tone and 5-HT1A serotonergic signaling. Useful for evening wind-down or stacking with daytime nootropics.

• 25 mg CBD per gummy · 30 ct bottle
• Vegan, gluten-free, broad-spectrum (no THC)
• Onset 30–90 min · 4–6 h duration
• Stacks with magnesium / L-theanine for deeper rest

Hemp-derived CBD (<0.3% THC) — federally legal under the 2018 Farm Bill; check your state for any local restrictions. COA available per batch. Not for use in pregnancy or with strong CYP3A4-metabolized medications without provider review.

Plant Pigments — All-in-One (or pick & choose)

Five evidence-leaning plant pigments designed to dampen systemic inflammation and improve LDL-cholesterol profile naturally. Take all five together or use the customizer to dial each one in — your provider can fine-tune the dose set against your latest lipid panel and hsCRP.

• Astaxanthin — algal carotenoid · anti-inflammatory + joint / oxidative-stress effects
• Lutein + Zeaxanthin — xanthophylls · macular eye support, antioxidant tone
• Lycopene — reduces LDL oxidation; cardiovascular + prostate evidence
• Anthocyanins — bilberry / black-currant flavonoids · vascular endothelium + lipid metabolism
• Stacks cleanly with metformin, CBD, and PEA on the longevity side; complements (not replaces) any prescription statin

Supplement-tier (DSHEA). Not FDA-approved to treat any disease or to lower cholesterol. Strongest LDL evidence: lycopene + anthocyanins; strongest oxidative-stress / inflammation evidence: astaxanthin + lutein/zeaxanthin. Provider reviews current lipid medications at intake.

BPC-157 — Sublingual

Body-Protection Compound 157, a stable pentadecapeptide studied for tendon, ligament, and gastrointestinal healing. Sublingual tincture avoids daily injections while keeping the peptide away from gastric hydrolysis.

• Pro-angiogenic + growth-factor upregulation
• Tendon, ligament, post-training recovery
• Typical dose: 250 µg / drop, 2–3× daily
• Provider-supervised compounded peptide

BPC-157 is a compounded research peptide. Not FDA-approved as a drug; prescribed off-label via state-licensed compounding pharmacies under your provider's clinical judgment.

TB-500 (Thymosin β4) — Sublingual

Synthetic fragment of thymosin beta-4 studied for soft-tissue repair, actin sequestration, and wound/myocardial healing. Sublingual route bypasses gastric breakdown without the needle.

• Actin-binding · tissue repair + angiogenesis
• Pairs with BPC-157 in protocols
• Typical dose: 500 µg / drop, 1–2× daily
• Provider-supervised compounded peptide

TB-500 is a compounded research peptide. Not FDA-approved as a drug; prescribed off-label via state-licensed compounding pharmacies under your provider's clinical judgment.

KPV (Lys-Pro-Val) — Oral

Tripeptide C-terminal fragment of α-MSH. Orally stable (rare among peptides), studied for mast cell stabilization, intestinal mucosal inflammation, and the symptom cluster seen in MCAS and IBD/Crohn's.

• α-MSH fragment — anti-inflammatory, mast-cell-modulating
• GI-stable — taken by mouth, no injection
• Typical dose: 250–500 µg, 1–2× daily
• Stacks with BPC-157 for stubborn gut-driven inflammation

KPV is a compounded peptide prescribed off-label for mast cell activation and inflammatory bowel conditions. Not FDA-approved as a drug; dispensed by state-licensed compounding pharmacies under provider evaluation.

Methylene Blue Troche

Low-dose compounded methylene blue as a slow-dissolve cheek troche (typically 5–15 mg). Acts as an alternative electron acceptor at Complex IV, supporting mitochondrial ATP output and cerebral oxygen utilization.

• ⚠️ G6PD deficiency screen required — can cause severe hemolysis
• ⚠️ MAO-A inhibitor — contraindicated with SSRIs / SNRIs (serotonin syndrome risk)
• Dissolves buccally over 5–10 minutes
• Morning dosing, alternate days
• Stains urine temporarily (harmless)

Pharmaceutical-grade (USP) only. Provider screens for G6PD deficiency via a quantitative enzyme assay and reviews all serotonergic drug interactions before dispensing. Details: G6PD explainer · Serotonin-syndrome warning.

Metformin ER — Healthspan Dose

Insulin sensitizer with 60+ years of safety data. Beyond diabetes, observational cohorts suggest lower all-cause mortality and reduced age-related disease incidence. Subject of the ongoing TAME trial — the first FDA-accepted aging endpoint study.

• 500 mg ER with dinner, titrate to 1000–1500 mg if tolerated
• AMPK activation · improved mitochondrial + insulin signaling
• Check eGFR + B₁₂ at baseline and annually
• Avoid if eGFR < 30 or significant hepatic disease

Off-label for non-diabetic metabolic optimization. Your provider confirms you don't have contraindications (renal impairment, lactic-acidosis risk, heavy alcohol use) before prescribing.

False Indigo (Baptisia tinctoria + Amorpha fruticosa)

Two related "false indigo" species, two jobs. Baptisia tinctoria is the Eclectic-era throat herb — used short-course for acute tonsillitis and upper-respiratory congestion, still a staple in European phytotherapy (often paired with echinacea + thuja). Amorpha fruticosa (false indigo bush) fruits are the source of amorfrutins — selective PPAR-γ partial agonists that hit the same receptor as the TZDs, with preclinical data for insulin sensitivity, hepatic fat, and anti-inflammatory signaling.

• Baptisia — standardized to quinolizidine alkaloids; short-course only (5–7 days during acute symptoms)
• Amorfrutins — standardized Amorpha extract, 2 capsules daily with food; stacks with metformin for metabolic coverage
• Selective PPAR-γ activity (less edema than TZDs)
• Not for chronic daily Baptisia use — alkaloid accumulation concerns

Traditional herbal + DSHEA supplement. Preclinical foundation for amorfrutins: Weidner et al., PNAS 2012. Don't self-treat a sore throat that could be strep — provider rules out bacterial infection first. Human RCT data for amorfrutins is thin but favorable for metabolic markers.

NR & NMN — NAD⁺ precursors

Two oral precursors that raise intracellular NAD⁺, the redox cofactor that declines with age and gates sirtuin + PARP activity, mitochondrial respiration, and DNA-damage response. NR (nicotinamide riboside) is the most-studied form — human RCTs show reliable whole-blood NAD⁺ elevation. NMN (nicotinamide mononucleotide) sits one step downstream and has growing human data for insulin sensitivity and physical function, though regulatory status has been contested in the U.S.

• NR — 300 mg once daily, with breakfast
• NMN — 250–500 mg once daily (oral or sublingual)
• Raises NAD⁺ → fuels SIRT1/3, PARP, CD38 pathways
• Stacks cleanly with methylene blue (electron transport) and metformin (AMPK)
• Non-flushing (unlike niacin) — safe for chronic daily use

DSHEA supplement in the U.S. for NR; NMN status has fluctuated (FDA 2022 drug-exclusion letter; ongoing industry challenges). We stock pharmaceutical-grade (≥99%) material from audited suppliers. Best-evidence clinical papers: Martens 2018 (NR · healthy middle-aged), Yoshino 2021 (NMN · insulin sensitivity in postmenopausal women), Igarashi 2022 (NMN · physical performance).

Low-Dose Naltrexone — Nasal

Compounded intranasal naltrexone (1.0–3.0 mg/spray). Bypasses first-pass hepatic metabolism for smoother pharmacokinetics and faster onset than oral LDN — without the classic bedtime drowsiness cycle.

• Paradoxical µ/δ-opioid receptor modulation
• Microglial quiescence — fibromyalgia, complex CRPS, Hashimoto's
• Non-addictive, non-opioid despite the name
• Baseline TSH + LFTs required

Oxytocin Nasal Spray

Compounded intranasal oxytocin at 24 IU/spray. Studied for social bonding, anxiolysis, autonomic regulation, and adjunct pain management via central oxytocinergic pathways.

• Intranasal delivery crosses the nose–brain axis
• Anxiolytic, prosocial, autonomic-calming use cases
• Typical dosing 1–2 sprays per nostril PRN
• Not for use during pregnancy

CJC-1295 + Ipamorelin — Subq

A growth-hormone-releasing-peptide stack: CJC-1295 (modified GHRH 1-29) extends the natural GH pulse, while Ipamorelin (a 5-aa ghrelin-receptor secretagogue) triggers it cleanly without spiking cortisol or prolactin. Studied for sleep depth, recovery, body composition, and lean muscle.

• Synchronized GHRH analog + selective GHS — physiologic pulse, not a depot
• Nightly subq before bed — 100 µg Ipamorelin + 100 µg CJC-1295 (no DAC) typical
• Supports REM, fat oxidation, and lean-mass retention without HGH side-effects
• 5-day-on / 2-day-off cycling reduces receptor desensitization

Compounded growth-hormone-releasing peptides; not FDA-approved as finished drugs. Provider screens for active malignancy, severe insulin resistance, and pituitary disease before prescribing.

MOTS-c — Mitochondrial Peptide

A 16-aa peptide encoded inside the mitochondrial 12S rRNA gene. Activates AMPK, restores insulin sensitivity, and shifts substrate utilization toward fat oxidation in preclinical work. Studied as an "exercise-mimetic" for metabolic regulation.

• Mitochondrial-derived peptide (MDP) — endogenous metabolic regulator
• AMPK activation · improved glucose disposal · enhanced fat oxidation
• Typical dose: 5–10 mg subq, 2–3× weekly
• Pairs with metformin or in metabolic-resistance protocols

Compounded peptide prescribed off-label for metabolic dysregulation. Human RCT data is early; preclinical foundation strong (Lee et al., Cell Metabolism 2015).

AOD-9604 — Fat Metabolism Peptide

A modified C-terminal fragment of human growth hormone (residues 177–191). Stimulates lipolysis and inhibits lipogenesis without engaging the IGF-1 axis — so you get the fat-metabolism end of HGH without the glucose-handling effects.

• hGH (177-191) fragment — fat-pathway-selective
• No IGF-1 elevation, no glucose impairment
• Typical dose: 300 µg subq, daily morning
• Studied as a lean-mass-sparing fat-loss adjunct

Compounded peptide; not FDA-approved as a finished drug for weight loss. Originally investigated by Metabolic Pharmaceuticals; Phase II showed modest fat-mass effect.

Thymosin α-1 — Immune Peptide

A 28-residue peptide naturally produced by the thymus. Enhances T-cell maturation and dendritic-cell antigen presentation. Used clinically (as Zadaxin) outside the U.S. for chronic hepatitis B/C, and increasingly studied as oncology supportive care and post-viral fatigue (long-COVID) adjunct.

• Approved & marketed in 30+ countries (not U.S. — compounded here)
• T-cell maturation · dendritic cell activation · NK-cell support
• Typical dose: 1.6 mg subq, 2× weekly
• Adjunctive in chronic viral infection and immune-suppressed states

Compounded peptide prescribed off-label in the U.S.; FDA-approved as a finished drug elsewhere (Zadaxin). Active malignancy and pregnancy are common screening flags.